UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2006
Gen-Probe Incorporated
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
001-31279
|
|
33-0044608 |
| (State or Other Jurisdiction of
|
|
(Commission
|
|
(I.R.S. Employer |
| Incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
|
|
| 10210 Genetic Center Drive
|
|
|
|
|
| San Diego, CA
|
|
|
|
92121 |
| (Address of Principal Executive Offices)
|
|
|
|
(Zip Code) |
(858) 410-8000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| |
|
|
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
On November 29, 2006, Gen-Probe Incorporated and 3M Company entered into an exclusive
collaboration agreement to develop, manufacture and market innovative nucleic acid tests to enhance
food safety and increase the efficiency of testing for food manufacturers.
A copy of the press release we issued with respect to the execution of the agreement is
furnished with this current report as Exhibit 99.1.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits. |
| |
(d) |
|
The following exhibit is furnished with this Current Report: |
| |
99.1 |
|
Press Release dated December 6, 2006 |
Forward-Looking Statements
Any statements in this Current Report on Form 8-K about Gen-Probe’s expectations,
beliefs, plans, objectives, assumptions or future events or performance are not historical facts
and are forward-looking statements. These statements are often, but not always, made through the
use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and
would. For example, statements concerning new food testing products and customer adoption are
forward-looking statements. Forward-looking statements are not guarantees of performance. They
involve known and unknown risks, uncertainties and assumptions that may cause actual results,
levels of activity, performance or achievements to differ materially from those expressed or
implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that
could cause actual results to differ materially from estimates or projections contained in the
forward-looking statements include but are not limited to: (i) the risk that development efforts
may not be timely or successful, (ii) the possibility that new products will not be competitive or
gain market acceptance, and (iii) the risk that collaborations cannot be maintained. The foregoing
describes some, but not all, of the factors that could affect our ability to achieve results
described in any forward-looking statements. For additional information about risks and
uncertainties and a discussion of our financial statements and footnotes, see documents we file
with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic
reports. We assume no obligation and expressly disclaim any duty to update any forward-looking
statement to reflect events or circumstances after the date of this Current Report on Form 8-K or
to reflect the occurrence of subsequent events.